CRYSTALLINE AND NON-CRYSTALLINE FORMS OF SGLT2 INHIBITORS
申请人:SCINOPHARM TAIWAN, LTD.
公开号:US20130237487A1
公开(公告)日:2013-09-12
The present invention provides amorphous forms and the crystalline complexes of SGLT2 inhibitors as a novel material, in particular in pharmaceutically acceptable form. The crystalline forms of SGLT2 inhibitor canagliflozin are designated as Forms CS1, CS2, CS3, CS4 and CS5.